Biotech Values

[walk]

Adolor fell 11.32, or 45%, to 13.65. One of two late-stage studies of an experimental drug for bowel dysfunction failed to show it was superior to a fake treatment, a setback for developers, Adolor, of Exton, Pa., and large-cap GlaxoSmithKline. Shares of Progenics Pharmaceuticals soared 2.56, or 11%, to 25.22 amid hopes that Adolor's news could help the prospects for a rival drug being co-developed by Progenics, of Tarrytown, N.Y., and large cap Wyeth.

another biotech waterfall...